Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia from Physician’s and Patient’s Perspective

Tatyana I Ionova, PhD, Tatyana P Nikitina, PhD, Denis A Fedorenko, MD PhD, Taras A Gritsenko, MD PhD, Valentina L Ivanova, MD PhD, Galina B Kuchma, MD PhD, Tatyana V Shnaider, MD PhD, Inga V Sannikova, MD PhD, Elena I Usacheva, MD PhD, Kira A Kurbatova

Blood (2014) 124 (21): 2644.

https://doi.org/10.1182/blood.V124.21.2644.2644

Published: 2014

Journal Articles

Efficacy Of Dasatinib Therapy In Patients With Imatinib-Resistant Or -Intolerant Chronic Myeloid Leukemia From Physician’s and Patient’s Perspective: “Real World” Data

Tatyana I Ionova, PhD, Tatyana P Nikitina, MD, Taras A Gritsenko, MD, PhD, Valentina L Ivanova, MD, PhD, Galina B Kuchma, MD, PhD, Tatyana V Shnaider, MD, PhD, Inga V Sannikova, MD, Denis A Fedorenko, MD, PhD, Kira A Kurbatova

Blood (2013) 122 (21): 5185.

https://doi.org/10.1182/blood.V122.21.5185.5185

Published: 2013

Journal Articles

Clinical and Patient-Reported Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia

Tatyana I Ionova, PhD, Tatiana P Nikitina, PhD, Taras A Gritsenko, MD, PhD, Valentina L Ivanova, MD, PhD, Galina B Kuchma, MD, PhD, Tatyana V Shnaider, MD, PhD, Denis A Fedorenko, MD, PhD, Kira A Kurbatova, Andrei A Novik, MD, PhD

Blood (2012) 120 (21): 4445.

https://doi.org/10.1182/blood.V120.21.4445.4445

Published: 2012

Journal Articles

Which Strategy of Immunoablative Therapy with Autologous Stem Cell Transplantation (ASCT) Is Preferable in Multiple Sclerosis (MS) Patients?.

Yury L. Shevchenko, Andrei A. Novik, Alexey N. Kuznetcov, Boris A. Afanasiev, Igor A. Lisukov, Oleg A. Rykavicin, Alexandr A. Myasnikov, Tatyana I. Ionova, PhD, Vladimir J. Melnichenko, MD, PhD, Denis A. Fedorenko, MD, PhD, Anton V. Kishtovich, PhD, Roman A. Ivanov, PhD, Gary J. Gorodokin, MD

Blood (2007) 110 (11): 5093.

https://doi.org/10.1182/blood.V110.11.5093.5093

Published: 2007

Journal Articles

Multicenter Experience of High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT) in Multiple Sclerosis (MS) Patients.

Blood (2006) 108 (11): 3072.

https://doi.org/10.1182/blood.V108.11.3072.3072

Published: 2006

Journal Articles

Treatment Outcomes in Multiple Sclerosis (MS) Patients after Early, Conventional and Salvage High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT).

Yury L. Shevchenko, Andrei A. Novik, Boris V. Afanasiev, Igor A. Lisukov, Tatiana I. Ionova, PhD, Andrei D. Kulagin, MD, Olga A. Malysheva, MD, Gennady N. Bisaga, MD, PhD, Vladimir J. Melnichenko, MD, PhD, Sergei V. Voloshin, MD, PhD, Denis A. Fedorenko, MD, PhD, Inna V. Vereschagina, MD, Anton V. Kishtovich, PhD, Yury N. Fedotov, MD, PhD, Gary I. Gorodokin, MD

Blood (2005) 106 (11): 5467.

https://doi.org/10.1182/blood.V106.11.5467.5467

Published: 2005

Journal Articles

Quality of Life (QoL) Impairment and International Prognostic Index (IPI) in New Aggressive Non-Hodgkin’s Lymphoma (ANHL) Patients.

Andrei A. Novik, Tatiana I. Ionova, PhD, Anton V. Kishtovich, PhD, Alexander A. Myasnikov, Tatiana V. Chagorova, MD, PhD, Mikhail V. Kopp, Nina E. Osipova, MD, Julia K. Lebedeva, MD, Natalia N. Malakchova, MD, Anastasia V. Pankova, Denis A. Fedorenko, MD, PhD, Gary I. Gorodokin, MD

Blood (2005) 106 (11): 4651.

https://doi.org/10.1182/blood.V106.11.4651.4651

Published: 2005

NARROW

Long-Term Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia from Physician’s and Patient’s Perspective

Efficacy Of Dasatinib Therapy In Patients With Imatinib-Resistant Or -Intolerant Chronic Myeloid Leukemia From Physician’s and Patient’s Perspective: “Real World” Data

Clinical and Patient-Reported Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia

Which Strategy of Immunoablative Therapy with Autologous Stem Cell Transplantation (ASCT) Is Preferable in Multiple Sclerosis (MS) Patients?.

Multicenter Experience of High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT) in Multiple Sclerosis (MS) Patients.

Treatment Outcomes in Multiple Sclerosis (MS) Patients after Early, Conventional and Salvage High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT).

Quality of Life (QoL) Impairment and International Prognostic Index (IPI) in New Aggressive Non-Hodgkin’s Lymphoma (ANHL) Patients.

Email alerts

ASH Publications

American Society of Hematology

Long-Term Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia from Physician’s and Patient’s Perspective

Efficacy Of Dasatinib Therapy In Patients With Imatinib-Resistant Or -Intolerant Chronic Myeloid Leukemia From Physician’s and Patient’s Perspective: “Real World” Data

Clinical and Patient-Reported Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia

Which Strategy of Immunoablative Therapy with Autologous Stem Cell Transplantation (ASCT) Is Preferable in Multiple Sclerosis (MS) Patients?.

Multicenter Experience of High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT) in Multiple Sclerosis (MS) Patients.

Treatment Outcomes in Multiple Sclerosis (MS) Patients after Early, Conventional and Salvage High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT).

Quality of Life (QoL) Impairment and International Prognostic Index (IPI) in New Aggressive Non-Hodgkin’s Lymphoma (ANHL) Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only